Is NERVGEN PHARMA CORP. (NGEN) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.0% / 30% | 5.5% / 30% | 0.1% / 30% | N/A | ✓ HALAL |
| DJIM | 0.0% / 33% | 5.5% / 33% | 0.1% / 33% | N/A | ✓ HALAL |
| MSCI | 0.5% / 33% | 89.1% / 33% | 2.1% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.0% / 33% | 5.5% / 33% | 0.1% / 33% | N/A | ✓ HALAL |
| FTSE | 0.5% / 33% | 89.1% / 33% | 2.1% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -820.1% | |
| Return on Assets (ROA) | -88.8% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$17M |
| Free Cash Flow | -$17M |
| Total Debt | $105,603 |
| Current Ratio | 0.8 |
| Total Assets | $19M |
Price & Trading
| Last Close | $3.66 |
| 50-Day MA | $4.22 |
| 200-Day MA | $3.40 |
| Avg Volume | 145K |
| Beta | 1.0 |
|
52-Week Range
$1.50
| |
About NERVGEN PHARMA CORP. (NGEN)
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is NERVGEN PHARMA CORP. (NGEN) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), NERVGEN PHARMA CORP. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is NERVGEN PHARMA CORP.'s debt ratio?
NERVGEN PHARMA CORP.'s debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.5%.
What are NERVGEN PHARMA CORP.'s key financial metrics?
NERVGEN PHARMA CORP. has a market capitalization of $290M. Return on equity stands at -820.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.